Reltecimod TFA
Description
Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs).
Product Information
| Product Name | Reltecimod TFA |
| Molecular Weight | 1037.19 (free base) |
| Formula | C46H72N10O15S.xC2HF3O2 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | {d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala} |
| Sequence Shortening | {d-Ala}-SPMLVAYD-{d-Ala} |
| Storage | Sealed storage, away from moisture and light Powder -80??C 2 years -20??C 1 year *In solvent : -80??C, 6 months; -20??C, 1 month (sealed storage, away from moisture and light) |
